C4 Therapeutics CCCC Stock
C4 Therapeutics Price Chart
C4 Therapeutics CCCC Financial and Trading Overview
| C4 Therapeutics stock price | 4 USD |
| Previous Close | 4.03 USD |
| Open | 4.1 USD |
| Bid | 2.91 USD x 200 |
| Ask | 5.1 USD x 200 |
| Day's Range | 3.94 - 4.1 USD |
| 52 Week Range | 1.69 - 5.17 USD |
| Volume | 1.16M USD |
| Avg. Volume | 3.08M USD |
| Market Cap | 492.1M USD |
| Beta (5Y Monthly) | 2.946 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.33 USD |
CCCC Valuation Measures
| Enterprise Value | 295.3M USD |
| Trailing P/E | N/A |
| Forward P/E | -4.010025 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 14.044366 |
| Price/Book (mrq) | 1.9880714 |
| Enterprise Value/Revenue | 8.428 |
| Enterprise Value/EBITDA | -2.969 |
Trading Information
C4 Therapeutics Stock Price History
| Beta (5Y Monthly) | 2.946 |
| 52-Week Change | 58.10% |
| S&P500 52-Week Change | 19.17% |
| 52 Week High | 5.17 USD |
| 52 Week Low | 1.69 USD |
| 50-Day Moving Average | 3.93 USD |
| 200-Day Moving Average | 2.97 USD |
CCCC Share Statistics
| Avg. Volume (3 month) | 3.08M USD |
| Avg. Daily Volume (10-Days) | 2.54M USD |
| Shares Outstanding | 123.03M |
| Float | 94.52M |
| Short Ratio | 9.21 |
| % Held by Insiders | 0.83% |
| % Held by Institutions | 102.03% |
| Shares Short | 30.43M |
| Short % of Float | 24.87% |
| Short % of Shares Outstanding | 24.73% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -289.43% |
| Operating Margin (ttm) | -397.87% |
| Gross Margin | 86.34% |
| EBITDA Margin | -283.82% |
Management Effectiveness
| Return on Assets (ttm) | -19.25% |
| Return on Equity (ttm) | -48.14% |
Income Statement
| Revenue (ttm) | 35.04M USD |
| Revenue Per Share (ttm) | 0.31 USD |
| Quarterly Revenue Growth (yoy) | 2.80% |
| Gross Profit (ttm) | 30.25M USD |
| EBITDA | -99448000 USD |
| Net Income Avi to Common (ttm) | -101416000 USD |
| Diluted EPS (ttm) | -0.91 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 253.66M USD |
| Total Cash Per Share (mrq) | 2.06 USD |
| Total Debt (mrq) | 56.86M USD |
| Total Debt/Equity (mrq) | 23 USD |
| Current Ratio (mrq) | 5.449 |
| Book Value Per Share (mrq) | 2.012 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -84870000 USD |
| Levered Free Cash Flow (ttm) | -43664000 USD |
Profile of C4 Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 490 Arsenal Way |
| ZIP | 02472 |
| Phone | 617 231 0700 |
| Website | https://www.c4therapeutics.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 104 |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA. Additionally, it has a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Q&A For C4 Therapeutics Stock
What is a current CCCC stock price?
C4 Therapeutics CCCC stock price today per share is 4 USD.
How to purchase C4 Therapeutics stock?
You can buy CCCC shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for C4 Therapeutics?
The stock symbol or ticker of C4 Therapeutics is CCCC.
Which industry does the C4 Therapeutics company belong to?
The C4 Therapeutics industry is Biotechnology.
How many shares does C4 Therapeutics have in circulation?
The max supply of C4 Therapeutics shares is 123.03M.
What is C4 Therapeutics Price to Earnings Ratio (PE Ratio)?
C4 Therapeutics PE Ratio is now.
What was C4 Therapeutics earnings per share over the trailing 12 months (TTM)?
C4 Therapeutics EPS is -0.91 USD over the trailing 12 months.
Which sector does the C4 Therapeutics company belong to?
The C4 Therapeutics sector is Healthcare.
C4 Therapeutics CCCC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26025.57 USD — |
-0.59
|
3.98B USD — | 25910.82 USD — | 26109.96 USD — | — - | 3.98B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12774.25 USD — |
-0.58
|
— — | 12718.14 USD — | 12816.46 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
7235.41 USD — |
-0.68
|
— — | 7170.25 USD — | 7244.82 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1359.9 USD — |
-0.58
|
— — | 1351.98 USD — | 1362.71 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
- {{ link.label }} {{link}}
